• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

    10/1/25 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCM alert in real time by email

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany.

    Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will be presented during the poster sessions.

    Details of the presentations are as follows:

    Abstract titlePresenter / Lead authorPresentation details


    SPONSORED STUDIES
      
    Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)Zhenhua Liu

    (Chengdu, China)
    2592MO

    Mini Oral Session 1:

    GU tumours, renal & urothelial

    Friday, Oct 17, 2025

    Karlsruhe Auditorium - Hall 5.2

    16:00 - 17:30 CEST
    A Fruquintinib Expanded Access Program (EAP) to Provide Treatment for Patients With Metastatic Colorectal Cancer (mCRC)Stefan Kasper-Virchow 

    (Essen, Germany)
    794P

    Poster Session:

    Colorectal cancer
    Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase 1b/2 studyN. Arvind Dasari 

    (Houston, USA)
    799P

    Poster Session:

    Colorectal cancer
    A novel artificial intelligence (AI) imaging biomarker of tumor vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC)Sara Lonardi 

    (Padua, Italy)
    804P

    Poster Session:

    Colorectal cancer
    Safety and tolerability of fruquintinib: Pooled analysis of three placebo-controlled studies in patients with metastatic colorectal cancerCathy Eng 

    (Nashville, USA)
    811P

    Poster Session:

    Colorectal cancer
    Association between Metabolic Syndrome (MetS) and clinical outcomes of Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer (EMC) Patients with pMMR Status: results from FRUSICA-1 studyDanbo Wang

    (Shenyang, China)
    1230eP

    Poster Session:

    Gynaecological Cancer
    ctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)Yongfeng Yu 

    (Shanghai, China)
    1954P 

    Poster Session:

    NSCLC, metastatic
    SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osiQuincy Siu-chung Chu 

    (Edmonton, Canada)
    1955P 

    Poster Session:

    NSCLC, metastatic
    MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real world (rw) studyJulia Rotow

    (Boston, USA)
    1956P 

    Poster Session:

    NSCLC, metastatic
       
    INVESTIGATOR-INITIATED STUDIES  
    Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trialFei Ma

    (Zhengzhou, China)
    2159P 

    Poster Session:

    Oesophagogastric cancer
    Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II StudyWangjun Liao

    (Guangzhou, China)
    898eP

    E-poster Session:

    Colorectal cancer
    The efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: a single arm, prospective, exploratory clinical studyQianqian Wang

    (Nanjing, China)
    929P

    Poster Session:

    Developmental therapeutics
    Surufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC: Monotherapy and Vinorelbine Combination RegimensYanfang Zheng

    (Guangzhou, China)
    1884P

    Poster Session:

    NSCLC, metastatic
    Surufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase II Results from a Single-Center TrialWenfeng Fang/ Li Zhang

    (Guangzhou, China)
    1887P

    Poster Session:

    NSCLC, metastatic
    Efficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancerSong Gao/ Jihui Hao

    (Tianjin, China)
    2236P

    Poster Session:

    Pancreatic cancer
    Efficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II StudyXiaowei Zhang/ Zhiguo Luo

    (Shanghai, China)
    2716P

    Poster Session:

    Sarcoma
       

    About Fruquintinib

    Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors ("VEGFR") -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

    About Savolitinib

    Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.

    About Surufatinib

    Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body's immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.

    About HUTCHMED

    HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

    Medical Information

    This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

    CONTACTS

    Investor Enquiries+852 2121 8200 / [email protected]
      
    Media Enquiries 
    FTI Consulting –+44 20 3727 1030 / [email protected]
    Ben Atwell / Alex Shaw+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
    Brunswick – Zhou Yi+852 9783 6894 (Mobile) / [email protected]
      
    Panmure LiberumNominated Advisor and Joint Broker
    Atholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500
      
    CavendishJoint Broker
    Geoff Nash / Nigel Birks+44 20 7220 0500
      
    Deutsche NumisJoint Broker
    Freddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000


    Primary Logo

    Get the next $HCM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCM

    DatePrice TargetRatingAnalyst
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    5/13/2025Buy → Hold
    HSBC Securities
    11/24/2023Hold → Buy
    Deutsche Bank
    5/4/2022Buy → Hold
    Deutsche Bank
    9/22/2021$46.00Buy → Neutral
    Goldman
    8/3/2021$52.00Buy
    Jefferies
    More analyst ratings

    $HCM
    SEC Filings

    View All

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    9/30/25 6:15:03 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    9/12/25 6:29:38 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    9/5/25 6:32:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HUTCHMED downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded HUTCHMED from Equal-Weight to Underweight and set a new price target of $13.75

    9/22/25 8:24:03 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED downgraded by HSBC Securities

    HSBC Securities downgraded HUTCHMED from Buy to Hold

    5/13/25 3:20:36 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED upgraded by Deutsche Bank

    Deutsche Bank upgraded HUTCHMED from Hold to Buy

    11/24/23 7:13:23 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany. Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer a

    10/1/25 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and via webcast on Friday, October 31, 2025. During the event, Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED, will share insights into the Company's R&D strategy and vision. This will include an overview of the Company's Antibody Targeted Therapy Conjugates platform, featuring its lead candidate HMPL-A251, as well as updates on late-stage pipeline development. The in-person event will be held in Shanghai from 3:00

    9/11/25 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $HCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

    SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

    2/13/23 3:54:30 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

    SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

    2/11/22 11:19:49 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by HUTCHMED (China) Limited (Amendment)

    SC 13D/A - HUTCHMED (China) Ltd (0001648257) (Filed by)

    2/7/22 6:12:18 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Financials

    Live finance-specific insights

    View All

    HUTCHMED to Announce 2024 Final Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chin

    2/19/25 3:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

    — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shang

    1/1/25 5:46:43 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED to Announce 2024 Half-Year Financial Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT /

    6/26/24 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Leadership Updates

    Live Leadership Updates

    View All

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

    3/5/25 5:00:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme

    11/20/24 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care